Impact of Gender on the Association between Low Serum Prolactin and Left Ventricular Mass in Subjects with Prediabetes

Article information

Diabetes Metab J. 2017;41(3):195-204

Publication date (electronic) : 2017 June 21

doi : https://doi.org/10.4093/dmj.2017.41.3.195

, Enas M. Elkhamisy ¹, Eman Elsayed ², Shaheer Kamal ³

¹Department of Internal Medicine, Mansoura Specialized Medical Hospital, Mansoura University Faculty of Medicine, Mansoura, Egypt.

²Department of Clinical Pathology, Mansoura University Faculty of Medicine, Mansoura, Egypt.

³Department of Cardiology, Mansoura Specialized Medical Hospital, Mansoura University Faculty of Medicine, Mansoura, Egypt.

Corresponding author: Mervat M. El-Eshmawy. Department of Internal Medicine, Mansoura Specialized Medical Hospital, Mansoura University Faculty of Medicine, Elgomhoria St, Mansoura 35516, Egypt. mervat2040@yahoo.com

Received 2016 September 03; Accepted 2017 January 20.

Abstract

Background

Low circulating prolactin hormone was associated with increased risk for type 2 diabetes mellitus. An inverse association of serum prolactin with cardiac remodeling was also previously suggested. Thus, the first question arises whether low serum prolactin is associated with adverse cardiac remodeling in subjects with prediabetes and if so what the impact of gender is? Second, could serum prolactin be considered a predictor of cardiac morbidity in those subjects? This study was conducted to assess prolactin level variations in relation to echocardiographic indices of cardiac remodeling among adult men and women with prediabetes.

Methods

This cross sectional study enrolled 80 subjects with prediabetic; 40 men and 40 women. Anthropometric measurements, plasma glucose, lipid profile, homeostasis model assessment of insulin resistance, white blood cells count, prolactin and echocardiography were assessed.

Results

Prolactin was significantly lower in men than in women with prediabetes. Left ventricular mass (LVM) was significantly higher in men than in women with prediabetes. The proportion of left ventricular hypertrophy (LVH) in men with prediabetes was 45% compared with 22.5% in women (P=0.03). We also found inverse independent associations of serum prolactin with LVM and LVH in men, but not in women.

Conclusion

In prediabetes, physiologically low serum prolactin is an independent predictor of increased LVM and LVH in adult men, but not in women. Prolactin may be a potential diagnostic biomarker for cardiac remodeling in adult men with prediabetes.

Keywords: Cardiac remodeling; Gender; Prediabetes; Prolactin

INTRODUCTION

Prediabetes is a high-risk state for diabetes that is typically defined as blood glucose concentrations higher than normal, but lowers than diabetes thresholds. Prevalence of prediabetes is increasing worldwide and more than 470 million people will have prediabetes by 2030 [1]. Around 5% to 10% of people with prediabetes become diabetic every year, with the same proportion converting back to normoglycaemia, although the conversion rate varies with population characteristics and prediabetes definitions [2].

Prolactin is a 23 kDa protein produced by the anterior pituitary gland in response to physiologic stress, sleep, pregnancy, nipple stimulation, and nursing; it is important for mammary gland development and differentiation during pregnancy and crucial for lactation and maternal behavior immediately after labor [3]. In addition to being a circulating hormone of pituitary origin, prolactin in humans is produced by non-pituitary sites including the endometrium, decidua, lymphocytes, brain, breast, and prostate, where it acts as a cytokine [4]. Besides its well-known lactogenic properties, prolactin is also a highly versatile hormone whose functions are related to reproduction, growth and development, metabolism, immune regulation, brain function, and behavior [5 6]. Maternal prolactin increases concurrently to insulin during the second half pregnancy and stimulates β-cell proliferation, insulin production, and insulin secretion [7]. Moreover, it has been found that the effect of prolactin on glucose metabolism is not confined to the period of pregnancy [6 8]. In a large community based study, high circulating prolactin was associated with lower prevalence of diabetes and impaired glucose regulation in middle-aged and elderly Chinese men and postmenopausal women [9].

Indeed, an inverse association of prolactin with cardiac remodeling was also previously suggested [10]. Cardiac remodeling referred to dynamic, incremental alterations in structure and function over the life course in the human heart [11]. The morphology of this progressive cardiac remodeling may be characterized by changes in multiple measurable echocardiographic indices including increased left ventricular mass (LVM), progressive left ventricular (LV) wall thickening, and a large spectrum of geometrical LV adaptations. These changes were associated with greater cardiovascular morbidity and mortality [12].

Therefore, the first question arises whether low serum prolactin is associated with adverse cardiac remodeling in subjects with prediabetes and if so what the impact of gender is? Second, could serum prolactin be considered a predictor of cardiac morbidity in those subjects? This study was conducted to assess serum prolactin level variations in relation to echocardiographic indices of cardiac remodeling; LVM and incident left ventricular hypertrophy (LVH); among adult men and women with prediabetes.

METHODS

This cross sectional study comprised 80 adults with prediabetes, 40 men and 40 premenopausal women, with a mean age of 45.31±4.47 years. Subjects with prediabetes were recruited from the Endocrinology and Obesity Outpatient Clinics at Mansoura Specialized Medical Hospital, Mansoura University, Egypt between February 2014 and January 2015. All subjects signed an informed consent and the study was approved by the Local Ethics Committee.

All study participants were subjected to a detailed medical history; data on physical activity were collected and participants underwent a clinical examination. Anthropometric measurements were obtained using standardized techniques; height was measured to the nearest 0.5 cm, body weight was measured to the nearest 0.1 kg, body mass index (BMI) was calculated as weight/height² (kg/m²) and waist circumference (WC) was measured at the highest point of the iliac crest. Blood pressure was taken in the sitting position after 10 minutes of rest using a random-zero sphygmomanometer. Prediabetes was defined based on World Health Organization criteria [13]; people are at high risk of developing diabetes if they have one of two distinct states: impaired fasting glucose defined as a fasting plasma glucose (FPG) concentration of ≥6.1 and <7.0 mmol/L, without impaired glucose tolerance (IGT), and IGT defined as a FPG concentration of <7.0 mmol/L and a 2-hour postload plasma glucose (PPG) concentration of ≥7.8 and <11.1 mmol/L, measured during a 75 g oral glucose tolerance test.

Exclusion criteria were diabetes, hypertension or the use of antihypertensive medications, aortic stenosis, prevalent or incident myocardial infarction, history of pituitary disease, thyroid disorders, hepatic or renal failure, infection, connective tissue disorders, malignancy, pregnancy, women taking birth control pills or hormone replacement therapy and smoking. We also excluded six subjects with prolactin levels exceeding normal values for our laboratory (>23.3 ng/mL for women and 15.2 ng/mL for men) and those who were taking drugs known to influence glucose and prolactin, i.e., metformin, thiazolidinediones, steroids, metoclopramide, cimetidine, or psychoanaleptics.

Laboratory assay

FPG and 2-hour PPG were assayed using commercially available kit, Cobas (Integra-400) supplied by Roche Diagnostics (Mannheim, Germany). Glycosylated hemoglobin (HbA1c) was measured as an index of metabolic control on a DCA 2000 analyzer, fast ion exchange resin (Roche Diagnostic). The reference range was 4.4% to 6.4%. Fasting serum insulin was assayed by a solid-phase, enzyme-labeled chemiluminescent immunometric assay using an immulite analyzer supplied by Siemens (DPC Cirrus inc., Los Angeles, CA, USA). Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated with the formula: HOMA-IR=[fasting insulin (µU/mL)×fasting glucose (mmol/L)/22.5] [14]. Total cholesterol, triglycerides, and high density lipoprotein cholesterol (HDL-C) were estimated by commercially available kits (Cobas Integra-400). Low density lipoprotein cholesterol was calculated according to Friedewald et al. [15]. White blood cells (WBCs) count was measured using Sysmex xs-500i (Sysmex Europe GmbH, Norderstedt, Germany; www.sysmex.europe.com/ifu). Prolactin levels were measured from frozen sera at −20℃ using electro chemiluminescent microparticle assay by Elecsys 2010 (Roche diagnostics; www.Roche.com); blood samples were drawn from the cubital vein in the supine position at morning after a minimum of 2-hour awaking time and 30 minutes of rest.

Two-dimensional and M-mode echocardiography was performed by certified physicians using a GE Vingmed vivid 3 ultrasound (GE Healthcare, Chicago, IL, USA). All data and measurements were stored digitally. LV dimensions (interventricular septum thickness [IVS], left ventricular posterior wall thickness [LVPWD], left ventricular diastolic dysfunction [LVDD], and left ventricular end-systolic dimension [LVDS]) were measured. LVM was calculated according to the following formula: LVM={0.80×[1.04×(LVDD+IVS+LVPWD)³−LVDD³]}+0.60/height^2.7 [16]. LVH was defined by a LVM >48 g/m^2.7 in men and >44 g/m^2.7 in women (Fig. 1) [16].

Fig. 1

Concentric left ventricular hypertrophy by echocardiography. IVSd, inter-ventricular septum diameter; LVIDd, diastolic left ventricular internal diameter; LVPWd, left ventricular posterior wall diameter; IVSs, systolic inter-ventricular septum; LVIDs, systolic left ventricular internal diameter; LVPWs, systolic left vetricular posterior wall thickness; HR, heart rate; EF, ejection fraction; FS, fraction shortening.

Statistical methods

Data entry and analysis were done using the SPSS version 17 (SPSS Inc., Chicago, IL, USA). The data were expressed as mean±standard deviation for normally distributed data, frequency and proportion for categorical data and median (minimum–maximum) for skewed data. Statistical comparison between two groups was assessed by Student t-test for parametric data and Mann-Whitney for nonparametric data. A chi-square test was performed to compare categorical data. Univariate analysis was performed with LVM as the dependent variable and other studied variables as the independent. Univariate analysis was also performed with prolactin as the dependent variable and other studied variables as the independent (significant variables were entered in the regression model as co-founders); association between serum prolactin and LVM was performed by linear regression analysis with adjustment of the cofounding variables (age, WC, 2-hour PPG, HbA1c, HOMA-IR, HDL-C, WBC) in multivariable models. Moderation analysis was done to clarify the effect of sex on association between prolactin and LVM by determination of change in R² significance between the two models; predictors in crude basal model were prolactin (is not centered) and sex (coded 1 for men and 0 for women), predictors in crude interaction model were prolactin, sex, and interaction between prolactin and sex. Moderation analysis was repeated after adjustment of the confounding variables affecting LVM. Logistic regression analysis was carried out to evaluate the association between prolactin and LVH prevalence in men and women with prediabetes with adjustment of the confounding variables in multivariate models. P≤0.05 was considered to be significant.

RESULTS

Table 1 presents the baseline characteristics of the study subjects stratified by sex. Prolactin was significantly lower in men than in women with prediabetes (5.57±1.46 vs. 7.16±1.79, P=0.008). LVM was significantly higher in men than in women with prediabetes (50.52±10.99 g/m^2.7 vs. 43.73±11.37 g/m^2.7, P=0.004). The proportion of LVH in men with prediabetes was 45% (18/40) compared with 22.5% (9/40) in women (P=0.03). No significant differences between men and women with regard to BMI, WC, blood pressure, plasma glucose, HbA1c, HOMA-IR, lipid profile, or WBC count.

Table 1

Baseline characteristics of the study population

With univariate analysis, LVM was significantly associated with age (B=0.69, P=0.01), WC (B=1.64, P>0.001), 2-hour PPG (B=0.02, P=0.01), HbA1c (B=21.53, P=0.003), HOMA-IR (B=4.86, P=0.01), HDL-C (B=−0.52, P=0.02), and WBC count (B=−0.52, P=0.02), whereas prolactin was significantly associated with WC (B=−0.04, P=0.03), 2-hour PPG (B=−0.08, P=0.008), HbA1c (B=−5.45, P=0.02), insulin (B=−0.41, P=0.03), HOMA-IR (B=−1.18, P=0.001), and WBC count (B=−3.91, P=0.001) (Supplementary Table 1).

We found a significant negative association between prolactin and LVM in men with prediabetes even after adjustment of other cofounding variables (age, WC, 2-hour PPG, HbA1c, HOMA-IR, HDL-C, and WBC) (B=−3.71; 95% confidence interval [CI], −5.86 to −1.56; P=0.001 in crude model; B=−2.46; 95% CI, −4.51 to −0.41; P=0.02 in adjusted model), whereas there was no significant association between prolactin and LVM in women (Table 2). The strength of the negative association between prolactin and LVM was significantly higher in men with prediabetes than in women (P values of R² changes were 0.02 and 0.03 in crude and adjusted models, respectively) (Supplementary Table 2).

Table 2

Association between serum prolactin and left ventricular mass in men and women with prediabetes

Furthermore, multiple logistic regression analysis was revealed a significant negative association between prolactin and prevalence of LVH in men with prediabetes after adjustment of confounding variables (odds ratio [OR], 0.39; 95% CI, 0.20 to 0.75; P=0.005 in crude model; OR, 0.39; 95% CI, 0.18 to 0.84; P=0.01 in adjusted model), whereas there was no significant association between prolactin and LVH in women (Table 3).

Table 3

Association between serum prolactin and left ventricular hypertrophy in men and women with prediabetes

DISCUSSION

In the present study, men with prediabetes had significantly lower serum prolactin than did women. Our results also showed significant negative associations between prolactin levels and 2-hour PPG and HbA1c. These results are in harmony with Balbach et al. [17] who found an inverse association between prolactin and type 2 diabetes mellitus (T2DM) risk in a large population based cross-sectional study. Conversely, Wang et al. [9] found that a physiologically high circulating prolactin levels were associated with a favorable glucose metabolic profile; lower levels of FPG, PPG, and HbA1c; in a large community based middle-aged and elderly men and postmenopausal women.

Prediabetes is associated with the simultaneous presence of insulin resistance and β-cell dysfunction; abnormalities that start before glucose changes are detectable [1]. In the current study, HOMA-IR was significantly high in men and women with prediabetes according to normal limit for HOMA-IR <2.87, moreover the low prolactin levels were significantly associated with fasting insulin and HOMA-IR. In agreement, Wang et al. [9] observed that serum prolactin associates with higher levels of HOMA-β; however, a strict linear relationship was not confirmed across prolactin quartiles. Although some studies support the view that prolactin promotes insulin secretion [18 19], other studies were not able to detect any correlation between prolactin and HOMA-IR [20 21]. However, the role of prolactin on glucose metabolism and insulin resistance depends on its circulating concentration. It is worth mentioning that the effect of a physiologically high prolactin levels and pathological hyperprolactinemia on glucose metabolism could be different; excessive high levels of prolactin exacerbate whole-body and hepatic insulin resistance and impair the insulin secretory capacity in patients with hyperprolactinemia caused by prolactinoma [20].

From a mechanistic perspective, prolactin takes a crucial part in regulating whole-body insulin sensitivity and glucose metabolism by increasing β-cell proliferation, promoting cumulative insulin secretion, and inhibiting key caspases of the extrinsic and intrinsic pathways leading to islets apoptosis, and modulating immune function [8 22 23 24]. Prolactin up-regulates β-cell glucose uptake and utilization, whereas glucose increases islet prolactin receptor expression and potentiates the effects of prolactin on cell cycle gene expression and DNA synthesis [25]. Physiologically elevated prolactin levels also improve hepatic insulin sensitivity [26] and have an indirect action by increasing hypothalamic dopamine synthesis leading to improvement of energy and glucose homeostasis [26 27].

Interestingly, recent studies revealed that human adipose tissue produces prolactin and also expresses prolactin receptors. Prolactin directly regulates adipose tissue function in down regulating lipoprotein lipase and fatty acid synthase [28 29], which consequently suppress lipogenesis. On the other hand, insulin inhibits prolactin expression and release from differentiated adipocytes, so the overall effect of insulin on prolactin is likely inhibitory [30]. Collectively, these results raise the prospect that prolactin levels affect energy homeostasis through its action as an adipokine and is involved in the manifestation of insulin resistance [31].

We demonstrated that LVM and LVH were significantly higher in men than in women with prediabetes. With univariate analysis, LVM was significantly associated with WC, 2-hour PPG, HbA1c, HOMA-IR, HDL-C, and WBC count. We also found inverse independent associations of serum prolactin with LVM and LVH in men, but not in women. These findings are in line with previously reported sex-specific patterns of cardiac remodeling [10 11 32]. In a previous cross-sectional study among 2,531 men with sexual dysfunction, low serum prolactin concentrations were associated with an adverse cardiometabolic profile including higher BMI, unfavorable lipid profile and higher prevalence of T2DM [33]. Additionally, Corona et al. [34] showed inverse associations of prolactin with an unhealthy metabolic phenotype and the metabolic syndrome in middle-aged and elderly men.

There are few potential explanations for the association of low prolactin concentrations with adverse cardiac remodeling in men since epidemiological studies about the cardiometabolic role of prolactin in men are scarce. Karino et al. [35] confirmed that higher total WBC, granulocyte, and neutrophil counts were associated with higher risk of incident coronary heart disease in a population of elderly Japanese-American men; supporting an association between inflammation and cardiovascular disease risk. This finding suggests that the unfavorable cardiometabolic risk profile associated with low prolactin concentrations in men may explain the adverse cardiac remodeling; however, in the present study population, lower serum prolactin was associated with adverse cardiac remodeling independently from other known risk factors.

The association between prolactin and sex hormones may be responsible for the association between prolactin and LV remodeling. The impact of estrogens on prolactin secretion is still not completely clear, partly because of non-physiological experiments and partly because of correlation studies that do not prove a causal role. So, the need for additional studies to explain this association may be warranted.

A potential role for prolactin in cardiac remodeling has been speculated since its 16 kDa N-terminal fragment was identified as a potential co-factor in the pathogenesis of peripartum cardiomyopathy [36], a disease characterized by LV systolic dysfunction and heart failure [37]. The proposed mechanism is unbalanced oxidative stress leading to activation of the protease cathepsin D, which acts to cleave full length 23 kDa prolactin to an angiostatic and proapoptotic 16 kDa form [37].

Prolactin activates the expression of signal transducer and activator of transcription 3 (STAT3) by means of its specific receptors in cardiomyocytes in the heart [36]. STAT3 has several cardioprotective functions in the heart, including protective effects against oxidative stress. Accordingly, the absence of cardioprotective systems like STAT3 could promote the fragmentation of prolactin into its 16 kDa component; thereby, leading to defective cardiac angiogenesis, heart failure, and subsequent mortality [38 39]. Halkein et al. [40] explore signaling downstream of prolactin fragment and demonstrate that microRNA-146a is a critical mediator of the antiangiogenic effects in endothelial cells, this study uncovers unexpected exosomal transfer of this microRNA to cardiomyocytes that may affect myocardial metabolism.

However, several limitations of the present investigation merit consideration. Firstly, we did not measure sex hormones or biomarkers of oxidative stress which may have influenced prolactin. Secondly, the generalizability of our results to other ethnicities and age groups is unknown. However, further large prospective studies in multiple ethnic groups are needed to confirm if serum prolactin could be considered a predictor of cardiac morbidity and mortality in patients with prediabetes.

ACKNOWLEDGMENTS

The authors thank all sample donors for their contribution to this study and all members of the Diabetes and Endocrinology Unit, Specialized Medical Hospital, Mansoura, Egypt.

Notes

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379:2279–2290. 22683128.

2. Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med 2007;24:200–207. 17257284.

3. Horseman ND. Prolactin and mammary gland development. J Mammary Gland Biol Neoplasia 1999;4:79–88. 10219908.

4. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extra-pituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639–669. 8969972.

5. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523–1631. 11015620.

6. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006;17:110–116. 16517173.

7. Huang C, Snider F, Cross JC. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology 2009;150:1618–1626. 19036882.

8. Labriola L, Montor WR, Krogh K, Lojudice FH, Genzini T, Goldberg AC, Eliaschewitz FG, Sogayar MC. Beneficial effects of prolactin and laminin on human pancreatic islet-cell cultures. Mol Cell Endocrinol 2007;263:120–133. 17081683.

9. Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, Xu B, Xu M, Chen Y, Bi Y, Wang W, Ning G. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care 2013;36:1974–1980. 23340889.

10. Haring R, Volzke H, Vasan RS, Felix SB, Nauck M, Dorr M, Wallaschofski H. Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP). Atherosclerosis 2012;221:570–576. 22293228.

11. Cheng S, Xanthakis V, Sullivan LM, Lieb W, Massaro J, Aragam J, Benjamin EJ, Vasan RS. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 2010;122:570–578. 20660804.

12. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001;87:1051–1057. 11348601.

13. World Health Organization. International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation Geneva: World Health Organization; 2006.

14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419. 3899825.

15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502. 4337382.

16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Chamber Quantification Writing Group. American Society of Echocardiography's Guidelines and Standards Committee. European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–1463. 16376782.

17. Balbach L, Wallaschofski H, Volzke H, Nauck M, Dorr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord 2013;13:12. 23517652.

18. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology 2004;145:4162–4175. 15142985.

19. Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N, Breant B, Kelly PA. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 2002;143:1378–1385. 11897695.

20. Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011;14:199–207. 21128120.

21. Ernst B, Thurnheer M, Schultes B. Basal serum prolactin levels in obesity: unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg 2009;19:1159–1162. 19430852.

22. Fleenor DE, Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology 2001;142:2805–2810. 11415999.

23. Fujinaka Y, Takane K, Yamashita H, Vasavada RC. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation. J Biol Chem 2007;282:30707–30717. 17728251.

24. Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 2009;9:23–27. 19248843.

25. Arumugam R, Fleenor D, Lu D, Freemark M. Differential and complementary effects of glucose and prolactin on islet DNA synthesis and gene expression. Endocrinology 2011;152:856–868. 21239441.

26. Park S, Kang S, Lee HW, Ko BS. Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats. Neuroendocrinology 2012;95:332–343. 22441304.

27. Lyons DJ, Hellysaz A, Broberger C. Prolactin regulates tuberoinfundibular dopamine neuron discharge pattern: novel feedback control mechanisms in the lactotrophic axis. J Neurosci 2012;32:8074–8083. 22674282.

28. Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003;88:1804–1808. 12679477.

29. Hogan JC, Stephens JM. The regulation of fatty acid synthase by STAT5A. Diabetes 2005;54:1968–1975. 15983196.

30. Hugo ER, Borcherding DC, Gersin KS, Loftus J, Ben-Jonathan N. Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab 2008;93:4006–4012. 18647802.

31. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007;9:464–476. 17587388.

32. Lieb W, Xanthakis V, Sullivan LM, Aragam J, Pencina MJ, Larson MG, Benjamin EJ, Vasan RS. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study. Circulation 2009;119:3085–3092. 19506113.

33. Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl 2011;34:217–224. 20522124.

34. Corona G, Wu FC, Rastrelli G, Lee DM, Forti G, O’Connor DB, O’Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Huhtaniemi IT, Kula K, Punab M, Vanderschueren D, Rutter MK, Maggi M. EMAS Study Group. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med 2014;11:240–253. 24345293.

35. Karino S, Willcox BJ, Fong K, Lo S, Abbott R, Masaki KH. Total and differential white blood cell counts predict eight-year incident coronary heart disease in elderly Japanese-American men: the Honolulu Heart Program. Atherosclerosis 2015;238:153–158. 25514532.

36. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589–600. 17289576.

37. Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart 2010;96:1352–1357. 20657009.

38. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 2005;107:131–137. 15963355.

39. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187–195. 15192020.

40. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013;123:2143–2154. 23619365.

Supplementary Materials

Supplementary Table 1

Univariate analysis with LVM and prolactin as the dependent variables in subjects with prediabetes

dmj-41-195-s001.pdf

Supplementary Table 2

Effect of sex on the association between serum prolactin and left ventricular mass in subjects with prediabetes

dmj-41-195-s002.pdf

Article information Continued

(open-access, http://creativecommons.org/licenses/by-nc/4.0/) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Characteristic	Men with prediabetes (n=40)	Women with prediabetes (n=40)
Age, yr	44.35±4.74	46.27±4.01
BMI, kg/m²	32.15±1.91	32.73±1.78
WC, cm	96.25±3.80	96.52±2.51
SBP, mm Hg	113.82±2.33	113.27±2.33
DBP, mm Hg	76.27±1.66	73.75±1.70
FPG, mg/dL	116.77±4.12	115.27±4.94
2-Hour PPG, mg/dL	175.52±13.60	169.12±19.61
HbA1c, %	6.02±0.20	5.98±0.15
Fasting insulin, µU/L	26.5 (25.0–29.8)	26.0 (25.0–28.0)
HOMA-IR	7.8 (7.3–8.6)	7.4 (7.1–8.0)
TC, mg/dL	232.22±44.69	224.35±31.33
TG, mg/dL	169.5 (151.3–180.0)	155.5 (145.0–174.3)
LDL-C, mg/dL	178.85±15.73	173.85±15.25
HDL-C, mg /dL	35.62±6.66	36.32±4.28
WBC count, ×10⁹/L	95.8±21.4	98.5±25.4
Prolactin, ng/mL	5.57±1.46^a	7.16±1.79
LVM, g/m^2.7	50.52±10.99^a	43.73±11.37
LVH	18 (45.0)^a	9 (22.5)

Model	Men with prediabetes		Women with prediabetes
Model	B (95% CI)	P value	B (95% CI)	P value
Crude	−3.71 (−5.86 to −1.56)	0.001^a	−0.17 (−2.27 to 1.93)	0.800
Adjusted^b	−2.46 (−4.51 to −0.41)	0.020^a	−0.77 (−2.74 to 1.20)	0.400

Model	Men with prediabetes		Women with prediabetes
Model	OR (95% CI)	P value	OR (95% CI)	P value
Crude	0.39 (0.20–0.75)	0.005^a	0.76 (0.49–1.19)	0.200
Adjusted^b	0.39 (0.18–0.84)	0.010^a	0.51 (0.24–1.09)	0.080